Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO Pharma's revenue for the
six
months ended in Dec. 2025 was NT$0.72 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.43 Mil.
CHO Pharma's Revenue per Share for the
six
months ended in Dec. 2025 was NT$0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.01.
During the past 13 years, CHO Pharma's highest 3-Year average Revenue per Share Growth Rate was 111.80% per year. The lowest was -43.30% per year. And the median was -12.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
CHO Pharma Revenue Related Terms
CHO Pharma Revenue Historical Data
* Premium members only.
The historical data trend for CHO Pharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CHO Pharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's Revenue distribution charts can be found below:
* The bar in red indicates where CHO Pharma's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$1.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHO Pharma (ROCO:6586) has a Revenue of NT$1.43 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on CHO Pharma and its competitors.
Is CHO Pharma's Revenue too high?
CHO Pharma's current Revenue is NT$1.43 Mil. Overall, CHO Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's Revenue compare to VRTX and REGN?
CHO Pharma's Revenue of NT$1.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on CHO Pharma and its competitors. CHO Pharma's current Revenue is NT$1.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current Revenue of NT$1.43 Mil. The current Revenue is NT$1.43 Mil. CHO Pharma's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current Revenue is NT$1.43 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
25GF Score
Get the complete analysis for ROCO:6586
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
